

## INFORMATION GUIDE

# Laboratory Monitoring for Persons Prescribed HIV PrEP

David H. Spach, MD<sup>1</sup> / Brian R. Wood, MD<sup>1</sup> / Raphael J. Landovitz, MD<sup>2</sup>

## TABLE OF CONTENTS

- 2 [TDF-FTC](#)
- 3 [TAF-FTC](#)
- 4 [CAB-LA](#)
- 5 [References,](#)  
[Acknowledgments,](#)  
[Funding](#)

### Abbreviations

TDF-FTC = Tenofovir DF-emtricitabine

TAF-FTC = Tenofovir alafenamide-emtricitabine

CAB-LA = Long-acting injectable cabotegravir

## ABOUT THIS INFORMATION GUIDE

This information guide is intended for health care professionals involved in care of persons interested in or receiving HIV preexposure prophylaxis (PrEP). This guide was created and produced by the University of Washington Infectious Diseases Education & Assessment Program (IDEA) as part of the federally-funded *National HIV PrEP Curriculum* project.

## SOURCES FOR LABORATORY MONITORING GUIDE

The laboratory monitoring tables are based on the 2021 Centers for Disease Control and Prevention (CDC) HIV PrEP Clinical Practice Guideline; some information in these tables have been slightly modified from the original CDC recommendations based on updated information and new CDC viral hepatitis screening recommendations.

## PERMISSION TO USE THIS GUIDE

This educational guide can reproduced without permission if used for noncommercial purposes.

## LAST UPDATED

This educational guide was last updated *February 5, 2024*.

### AUTHOR AFFILIATIONS

<sup>1</sup> Division of Allergy and Infectious Diseases / University of Washington

<sup>2</sup> Division of Infectious Diseases / University of California, Los Angeles

Table based on 2021 CDC Clinical Practice Guidelines for HIV PrEP

Laboratory Evaluation in Persons Taking Tenofovir DF-Emtricitabine (TDF-FTC) HIV PrEP

Test	Initial visit	Q 3 months	Q 6 months	Q 12 months	When stopping
 HIV-1 RNA	If indicated <sup>#</sup>	ALL			ALL
 HIV Antigen/ Antibody	ALL <sup>*¶</sup>	ALL <sup>¶</sup>			ALL <sup>¶</sup>
 Renal Function (eCrCl)	ALL		Age ≥50 years <b>OR</b> baseline eCrCl <90 mL/min	Age <50 years <b>AND</b> baseline eCrCl ≥90 mL/min	ALL
 Syphilis Serology	ALL	MSM/TGW	MSW/WSM		MSM/TGW
 Gonorrhea	ALL	MSM/TGW	MSW/WSM		MSM/TGW
 Chlamydia	ALL	MSM/TGW	MSW/WSM		MSM/TGW
 Hepatitis B Serology	ALL <sup>+</sup>				
 Hepatitis C Serology	ALL <sup>+</sup>			MSM/TGW and/or PWID	
 Pregnancy Test	ALL <sup>^</sup>	ALL <sup>^</sup>			

**LEGEND:**

- # Not routinely recommended, but order if any of the following apply: (1) received oral HIV PrEP or HIV PEP medications in past 3 months; (2) received cabotegravir injection in the past 12 months; (3) had high-risk exposure to HIV in prior 4 weeks; (4) has symptoms that suggest acute HIV.
- \* Perform within 7 days of starting HIV PrEP
- ¶ Laboratory-based preferred. Point of care blood acceptable but oral fluid testing not recommended.
- + One-time screening recommended for all adults in the United States. Give hepatitis B immunization if nonimmune.
- ^ For persons with childbearing potential; advised for counseling purposes

**ABBREVIATIONS:**




MSM = men who have sex with men; TGW = transgender woman; MSW = men who have sex with women; WSM = women who have sex with men; PWID = persons who inject drugs

**EDITOR'S NOTES**

1. Inability to order HIV-1 RNA testing should not preclude the use of TDF-FTC for HIV PrEP.
2. These recommendations pertain to persons taking daily oral TDF-FTC or on-demand (2-1-1) TDF-FTC.
3. Individuals who develop symptoms consistent with an STI should undergo prompt STI testing and receive appropriate treatment as clinically indicated; this evaluation should occur regardless of when the next routine STI screening is due.

Table based on 2021 CDC Clinical Practice Guidelines for HIV PrEP

Laboratory Evaluation in Persons Taking Tenofovir Alafenamide-Emtricitabine (TAF-FTC) HIV PrEP

Test	Initial visit	Q 3 months	Q 6 months	Q 12 months	When stopping
 HIV-1 RNA	If indicated <sup>#</sup>	ALL			ALL
 HIV Antigen/ Antibody	ALL <sup>*¶</sup>	ALL <sup>¶</sup>			ALL <sup>¶</sup>
 Renal Function (eCrCl)	ALL		Age ≥50 years <b>OR</b> baseline eCrCl <90 mL/min	Age <50 years <b>AND</b> baseline eCrCl ≥90 mL/min	ALL
 Syphilis Serology	ALL	MSM/TGW	MSW/WSM		MSM/TGW
 Gonorrhea	ALL	MSM/TGW	MSW/WSM		MSM/TGW
 Chlamydia	ALL	MSM/TGW	MSW/WSM		MSM/TGW
 Hepatitis B Serology	ALL <sup>+</sup>				
 Hepatitis C Serology	ALL <sup>+</sup>			MSM/TGW and/or PWID	
 Lipid Panel	ALL			ALL	
 Pregnancy Test	ALL <sup>^</sup>	ALL <sup>^</sup>			

**LEGEND:**

- # Not routinely recommended, but order if any of the following apply: (1) received oral HIV PrEP or HIV PEP medications in past 3 months; (2) received cabotegravir injection in the past 12 months; (3) had high-risk exposure to HIV in prior 4 weeks; (4) has symptoms that suggest acute HIV.
- \* Perform within 7 days of starting HIV PrEP
- ¶ Laboratory-based preferred. Point of care blood acceptable but oral fluid testing not recommended.
- ^ For persons with childbearing potential; advised for counseling purposes
- + One-time screening recommended for all adults in the United States. Give hepatitis B immunization if nonimmune.

**ABBREVIATIONS:**


MSM = men who have sex with men; TGW = transgender woman; MSW = men who have sex with women; WSM = women who have sex with men; PWID = persons who inject drugs

**EDITOR'S NOTES**

1. Inability to order HIV-1 RNA testing should not preclude the use of TAF-FTC for HIV PrEP.
2. Individuals who develop symptoms consistent with an STI should undergo prompt STI testing and receive appropriate treatment as clinically indicated; this evaluation should occur regardless of when the next routine STI screening is due.

Table based on 2021 CDC Clinical Practice Guidelines for HIV PrEP

Laboratory Evaluation in Persons Receiving Injectable Cabotegravir (CAB-LA) for HIV PrEP

TEST	Initial visit	1 month	Q2 months	Q4 months	Q6 months	Q12 months	When stopping
 HIV-1 RNA	ALL <sup>*</sup>	ALL	ALL				ALL
 HIV Antigen/ Antibody	ALL <sup>*¶</sup>	ALL <sup>¶</sup>	ALL <sup>¶</sup>				ALL <sup>¶</sup>
 Syphilis	ALL			MSM/TGW	MSW/WSM		MSM/TGW
 Gonorrhea	ALL			MSM/TGW	MSW/WSM		MSM/TGW
 Chlamydia	ALL			MSM/TGW	MSW/WSM		MSM/TGW
 Hepatitis B Serology	ALL <sup>+</sup>						
 Hepatitis C Serology	ALL <sup>+</sup>					MSM/TGW and/or PWID	
 Pregnancy Test	ALL <sup>^</sup>			ALL <sup>^</sup>			

LEGEND:

- \* Perform within 7 days of starting HIV PrEP. If an oral cabotegravir lead-in is used, the initial HIV testing should be done within 7 days of starting the oral lead-in and repeated within 7 days of the first cabotegravir injection.
- ¶ Laboratory-based preferred. Point of care blood acceptable but oral fluid testing not recommended.
- + One-time screening recommended for all adults in the United States. Give hepatitis B immunization if nonimmune.
- ^ For persons with childbearing potential; advised for counseling purposes

ABBREVIATIONS:

MSM = men who have sex with men; TGW = transgender woman; MSW = men who have sex with women; WSM = women who have sex with men; PWID = persons who inject drugs

EDITOR'S NOTES

1. Results for the HIV RNA and Ag/Ab should be available prior to administering the first cabotegravir injection. For all subsequent injections, the laboratory studies can be drawn on the same day the injection is given.
2. Individuals who develop symptoms consistent with an STI should undergo prompt STI testing and receive appropriate treatment as clinically indicated; this evaluation should occur regardless of when the next routine STI screening is due.

## REFERENCES

- Centers for Disease Control and Prevention (CDC). Discordant results from reverse sequence syphilis screening--five laboratories, United States, 2006-2010. *MMWR Morb Mortal Wkly Rep.* 2011;60:133-7. [[PMID1307823](#)]
- Centers for Disease Control and Prevention: US Public Health Service: Preexposure prophylaxis for the prevention of HIV infection in the United States—2021 Update: a clinical practice guideline. December 2021:1-108. [[CDC](#)].
- Connors EE, Panagiotakopoulos L, Hofmeister MG, et al. Screening and testing for hepatitis B virus infection: CDC Recommendations - United States, 2023. *MMWR Recomm Rep.* 2023;72:1-25. [[PMID 36893044](#)]
- Gandhi RT, Bedimo R, Hoy JF, et al. Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2022 Recommendations of the International Antiviral Society-USA Panel. *JAMA.* 2023;329:63-84. [[PMID 36454551](#)]
- Knox J, Tabrizi SN, Miller P, et al. Evaluation of self-collected samples in contrast to practitioner-collected samples for detection of *Chlamydia trachomatis*, *Neisseria gonorrhoeae*, and *Trichomonas vaginalis* by polymerase chain reaction among women living in remote areas. *Sex Transm Dis.* 2002;29:647-54. [[PMID 12438900](#)]
- Satyaputra F, Hendry S, Braddick M, Sivabalan P, Norton R. The laboratory diagnosis of Syphilis. *J Clin Microbiol.* 2021;59:e0010021. [[PMID 33980644](#)]
- Schillie S, Wester C, Osborne M, Wesolowski L, Ryerson AB. CDC Recommendations for hepatitis C screening among adults - United States, 2020. *MMWR Recomm Rep.* 2020;69:1-17. [[PMID 32271723](#)]

## DISCLOSURES

Dr. Spach, Dr. Wood, and Dr. Landovitz have no disclosures.

## ACKNOWLEDGEMENT

The authors would like to thank Peter Harrison, MPH and Carol Kono-Noble for their design and production work.

## FUNDING

The National HIV PrEP Curriculum is supported by the Centers for Disease Control and Prevention (CDC) and the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) as a part of a financial assistance award totaling \$625,000 from CDC and \$300,005 from HRSA with 0% financed with non-governmental sources. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement by CDC, HRSA, or HHS, or the U.S. Government. This project is led by the University of Washington Infectious Diseases Education & Assessment (IDEA) Program.

